For decades, the KRAS gene was considered untouchable. A single mutation in this gene drives rapid cell division in pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Drugs that tried to block it failed.
Resistance built fast. Patients ran out of options.
Now a team at Florida A&M University College of Pharmacy and Pharmaceutical Sciences is testing a different approach. Their compounds — polyisoprenylated cysteinyl amide inhibitors, or PCAIs — don’t target one specific KRAS mutation. They disrupt the abnormal protein interactions that mutant KRAS uses to signal cells to grow and move.
In lab tests, PCAIs stopped 90% of cell migration. That is the process by which cancer spreads.
Pancreatic cancer metastasizes early. It is aggressive. The limited number of drugs available quickly lose effectiveness because tumors develop intrinsic resistance.
The researchers, in their paper published in the journal Oncotarget, put it plainly: “The limited number of drugs to treat KRAS-driven cancers remains a significant healthcare problem, with the current drugs becoming ineffective due to intrinsic resistance.” Their conclusion: “novel therapies are needed to combat the KRAS conundrum.” The Florida A&M tests were conducted on pancreatic cancer cells grown in a lab. That is a controlled environment. It is not the human body.
But the data showed something striking — 90% of migration halted. For a disease that spreads while patients still feel fine, that number matters.
Why PCAIs might work where other drugs fail comes down to strategy. Most existing drugs try to block a single KRAS mutation. Cancer cells adapt.
They find workarounds. The PCAIs attack the signaling pathways themselves — the network of interactions that mutant KRAS uses to drive growth and movement.
Disrupt the network, not just one node, and the cancer has fewer escape routes. This is still early. Lab results do not always translate to patients.
But the KRAS conundrum the researchers describe has stymied oncology for years. Every new drug that showed initial promise eventually encountered resistance. The PCAIs represent a different logic — one that aims to outsmart the cycle of adaptation rather than just block a single target.
The practical stakes are clear. Pancreatic cancer kills quickly.
Most patients are diagnosed after it has already spread. Current drugs buy months, not years. If PCAIs can maintain even a fraction of that 90% inhibition in living tissue, the treatment landscape could shift.
Not overnight. Not without trials.
But the direction is different. Florida A&M’s team is testing compounds engineered to disrupt abnormal protein interactions associated with mutant KRAS signaling. They are not trying to fix the mutation.
They are trying to make it irrelevant. That is a significant departure from the “undruggable” label that KRAS has carried for years. The paper in Oncotarget lays out the data.
The lab tests show 90% cell migration halted. The next steps will determine whether that translates into real-world treatment.
For now, the researchers have found something that makes pancreatic cancer cells stop moving. In a disease defined by its relentless spread, that is a start.
